Tropic Biosciences Spins out Laverock Therapeutics to develop next-gen Programmable Cell Therapies
Stevenage, UK, 31st August 2022 / Sciad Newswire / Laverock Therapeutics Ltd was founded to develop a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of an experienced senior management team. Laverock’s mission is to utilise Gene Editing induced Gene Silencing (GEiGS®) tech
